View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 8, 2021

Coronavirus company news summary – Moderna applies to EMA for Covid-19 vaccine use among teens – Republic of Congo approves single-dose Sputnik Light vaccine

By Chris Lo

Moderna has submitted a conditional marketing approval (CMA) request to the European Medicines Agency for the use of its Covid-19 vaccine among adolescents. The submission comes after a Phase II/III study of the mRNA-1273 vaccine in adolescents aged between 12 and 18 years in the US. In May, the company announced that its Phase II/III TeenCOVE study of Moderna’s vaccine in adolescents met its primary immunogenicity endpoint.

The Ministry of Health of the Republic of Congo has approved the Russian-produced single-dose Sputnik Light vaccine to fight Covid-19. Sputnik Light is the first component of the Sputnik V vaccine and has shown 79.4% efficacy according to analysed data from 28 days after the administration of a single jab. The data was drawn from Russians vaccinated with a single jab and having not yet received the second, the Russian Direct Investment Fund said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology